Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a ...
Russian mRNA cancer 'vaccine' shows promise in pre-clinical trials, part of growing immunotherapy trend in cancer treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback